The present invention relates to a novel process for preparing ceftaroline fosamil as well as to a intermediates of formulae (1), (3) or (4) of this process.

The present invention relates to novel crystalline forms of ceftaroline fosamil and to methods for their preparation.

No clinical drug-drug interaction studies have been conducted with ceftaroline fosamil.

Furthermore the present invention relates to the use of the novel forms of ceftaroline fosamil for the preparation of an antibiotic medicament.

The present invention relates to a novel process for preparing ceftaroline fosamil as well as to intermediates of this process.

Ceftaroline fosamil is marketed as TEFLARO™ in the U.S.

In addition the present invention relates to pharmaceutical compositions comprising an effective amount of the novel forms of ceftaroline fosamil and to methods of preparing the same.

The effects of ceftaroline fosamil on fertility on humans have not been studied.

Home Allergan Announces FDA Approval of Updated Label for TEFLARO® (ceftaroline fosamil)

Allergan Announces FDA Approval of Updated Label for TEFLARO® (ceftaroline fosamil)

Finally the present invention relates to pharmaceutical combinations comprising an effective amount of the novel forms of ceftaroline fosamil and β-lactamase inhibitors.

The infusion solution concentration during preparation and administration should not exceed 12 mg/ml ceftaroline fosamil.

Patients who have a history of hypersensitivity to cephalosporins, penicillins or other beta-lactam antibacterials may also be hypersensitive to ceftaroline fosamil.

In such circumstance, the discontinuation of therapy with ceftaroline fosamil and the use of supportive measures together with the administration of specific treatment for Clostridium difficile should be considered.

The interaction potential of ceftaroline or ceftaroline fosamil on medicinal products metabolised by CYP450 enzymes is expected to be low since they are not inhibitors nor inducers of CYP450 enzymes in vitro.